Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : EU both claim a win in vaccine delivery tussle

06/18/2021 | 10:30am EDT

BRUSSELS (AP) — A Belgian court ruled Friday that coronavirus vaccine-maker AstraZeneca had committed a “serious breach” of its contract with the European Union amid a major legal battle over delivery obligations that has tarnished the company’s image.

The court ordered AstraZeneca to deliver a total of 80.2 million doses to the EU from the time the contract was agreed up until Sept. 27. The ruling said the company did not appear to have made a “best reasonable effort” to meet the delivery schedule because it had not used its U.K. production sites.

But the Anglo-Swedish company claimed victory, saying that this was far fewer than the 120 million doses that the EU’s executive branch, the European Commission, was seeking in total by the end of June. It also welcomed the court’s acknowledgement that it was under unprecedented pressure.

AstraZeneca was seen as a key pillar of the EU’s vaccine rollout. Its contract with the Commission foresaw an initial 300 million doses being distributed, with an option for another 100 million, but the speed of deliveries was far slower than the company originally thought.

“We are pleased with the Court’s order,” Executive Vice-President Jeffrey Pott said in a statement. “AstraZeneca has fully complied with its agreement with the European Commission and we will continue to focus on the urgent task of supplying an effective vaccine.”

The Commission, for its part, also claimed a victory in that the judge had ordered the company to respect a delivery schedule of 15 million doses by July 26, 20 million doses by August 23 and 15 million doses by Sept. 27. It ordered a fine of 10 euros ($12) per dose not delivered.

“This decision confirms the position of the Commission: AstraZeneca did not live up to the commitments it made in the contract. It is good to see that an independent judge confirms this,” Commission President Ursula von der Leyen said.

“This shows that our European vaccination campaign not only delivers for our citizens day by day. It also demonstrates that it was founded on a sound legal basis,” she said in a statement.

AstraZeneca’s image has been hurt by the slow pace of its vaccine production, but despite EU dissatisfaction with the speed of deliveries the Commission still recommends the company’s shots as effective protection against the coronavirus.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about ASTRAZENECA PLC
02:40pPFIZER : Brazil reopens amid looming threat from delta variant
02:10pRelaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
01:55pCORONAVIRUS – TUNISIA : Belgium sends emergency aid to Tunisia in the figh..
08:28aASTRAZENECA : Secures FDA Approval for Bydureon BCise Injectable Suspension for ..
06:26aAstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediat..
05:06aCORRECTION : AstraZeneca Says Data Shows One Dose of COVID-19 Jab 'Highly Effect..
04:48aASTRAZENECA : Single-Dose COVID-19 Jab Shows Effect Against Beta, Gamma, Delta V..
04:43aAstraZeneca's Covid-19 Vaccine Effective Against Variants After One Dose, Can..
04:31aT&T GROUP : Le gouvernement vietnamien soutient T&T Group pour l'achat de 40 mil..
04:08aASTRAZENECA : Vaxzevria is highly effective after one dose against severe diseas..
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 33,0x
Yield 2021 2,42%
Capitalization 181 B 181 B -
EV / Sales 2021 6,04x
EV / Sales 2022 5,26x
Nbr of Employees 76 100
Free-Float 81,1%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 116,50 $
Average target price 132,19 $
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.50%155 197
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
NOVARTIS AG0.20%207 246